What is Oruka Therapeutics, Inc.'s interest coverage?

Oruka Therapeutics, Inc. (ORKA) reported interest coverage of -49.7× in Q4 2024.

What does interest coverage mean?

Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.

Oruka Therapeutics, Inc. ORKA Interest coverage

Interest coverage at other companies

Johnson & JohnsonJNJ

24.5×-1.7×

AmgenAMGN

3.9×+1.5×

MoonLake ImmunotherapeuticsMLTX

-28.2×-14.1×

Arcutis Biotherapeutics, Inc.ARQT

-2.6×-1.0×

ImmunityBio, Inc.IBRX

-5×-1.1×

Inhibrx Biosciences, Inc.INBX

-9.5×-4.0×

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$4.95B+533%

Enterprise value$4.9B+690%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

ebit/interest expense=-49.7×

Based on trailing twelve months.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s interest coverage?: Oruka Therapeutics, Inc. (ORKA) reported interest coverage of -49.7× in Q4 2024.
What does interest coverage mean?: Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.